Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)
- 26 June 2007
- Vol. 110 (4), 759-763
- https://doi.org/10.1002/cncr.22839
Abstract
BACKGROUND. Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS‐247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi‐institutional setting in patients previously treated with 1 prior chemotherapy regimen. METHODS. Forty‐five patients with advanced urothelial carcinoma were treated with BMS‐247550 40 mg/m2 over 3 hours intravenously on Day 1 of a 21‐day cycle and continued therapy until progression or unacceptable toxicity. RESULTS. Five patients obtained an objective partial response (PR) among the 42 eligible patients for an overall response rate of 11.9% (90% confidence interval [5.3%, 26.5%]). Median overall survival of the group was 8 months. Toxicity was moderate with granulocytopenia, fatigue, and sensory neuropathy being the most common side effects noted. CONCLUSIONS. BMS‐247550 (ixabepilone) has very modest activity as a second‐line therapy for advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and sensory neuropathy was common. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 24 references indexed in Scilit:
- Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the UrotheliumJournal of Clinical Oncology, 2006
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenBritish Journal of Cancer, 2006
- Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111Journal of Clinical Oncology, 2005
- Epothilones: Mechanism of Action and Biologic ActivityJournal of Clinical Oncology, 2004
- Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology GroupJournal of Clinical Oncology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003
- Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)Journal of Biological Chemistry, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958